Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorJanjigian, Yelena
dc.contributor.authorVan Cutsem, Eric
dc.contributor.authorMuro, Kei
dc.contributor.authorWainberg, Zev
dc.contributor.authorAl-Batran, Salah-Eddin
dc.contributor.authorHyung, Woo Jin
dc.contributor.authorTabernero Caturla, Josep
dc.date.accessioned2022-09-06T11:20:26Z
dc.date.available2022-09-06T11:20:26Z
dc.date.issued2022-06
dc.identifier.citationJanjigian YY, Van Cutsem E, Muro K, Wainberg Z, Al-Batran SE, Hyung WJ, et al. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. Futur Oncol. 2022 Jun;18(20):2465–2473.
dc.identifier.issn1479-6694
dc.identifier.urihttp://hdl.handle.net/11351/8033
dc.descriptionChemotherapy; Durvalumab; Gastric cancer
dc.description.abstractStandard-of-care for resectable gastric/gastroesophageal junction cancer includes surgery and neoadjuvant-adjuvant 5-fluorouracil-leucovorin-oxaliplatin-docetaxel (FLOT) chemotherapy. Early-phase clinical studies support further clinical development of the immune checkpoint inhibitor (ICI); durvalumab, an anti-PD-L1 antibody, in patients with gastric/gastroesophageal junction cancer. Accumulating evidence indicates that ICIs combined with FLOT chemotherapy improve clinical outcomes in patients with advanced or metastatic cancer. We describe the rationale for and the design of MATTERHORN, a randomized, double-blind, placebo-controlled, phase III study investigating the efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy followed by adjuvant durvalumab monotherapy in patients with resectable gastric/gastroesophageal junction cancer. The planned sample size is 900 patients, the primary end point is event-free survival and safety and tolerability will be evaluated.
dc.language.isoeng
dc.publisherFuture Medicine
dc.relation.ispartofseriesFuture Oncology;18(20)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectEstómac - Càncer - Tractament
dc.subjectQuimioteràpia combinada
dc.subject.meshStomach Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshNeoadjuvant Therapy
dc.titleMATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.2217/fon-2022-0093
dc.subject.decsneoplasias gástricas
dc.subject.decs/farmacoterapia
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada
dc.subject.decstratamiento neoadyuvante
dc.relation.publishversionhttps://doi.org/10.2217/fon-2022-0093
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Janjigian YY] Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. [Van Cutsem E] Department of Gastroenterology/Digestive Oncology, University Hospitals Leuven & KU Leuven, Leuven, 3000, Belgium. [Muro K] Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, 464-8681, Japan. [Wainberg Z] Department of Gastrointestinal Medical Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90404, USA. [Al-Batran SE] Institute of Clinical Cancer Research, Krankenhaus Nordwest, University Cancer Center, Frankfurt, 60488, Germany. [Hyung WJ] Department of Surgery, Yonsei University College of Medicine, Seoul, 03722, South Korea. [Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, 08035, Spain
dc.identifier.pmid35535555
dc.identifier.wos000804192000001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record